LGVN

LGVN

USD

Longeveron Inc. Class A Common Stock

$0.800-0.020 (-2.439%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$0.820

High

$0.820

Low

$0.800

Volume

0.38M

Company Fundamentals

Market Cap

16.8M

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

0.95M

Exchange

NCM

Currency

USD

52-Week Range

Low $0.633Current $0.800High $2.31

Related News

GlobeNewswire

Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions,

View more
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
GlobeNewswire

Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHSFull enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II)

View more
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect